Exosens H1 FY26 adjusted EBITDA rises 18.3% to €83.6 million; revenue climbs 15.3% to €253.1 million

• Exosens posted H1 2026 revenue of €253.1 million, up 15.3% year over year; operating income fell to €31.2 million from a €28.2 million trademark impairment.
• Adjusted EBITDA rose 18.3% to €83.6 million, lifting margin to 33% from 32.2%.
• Net profit dropped 45% to €15.3 million; net profit from continued operations excluding impairment climbed 21.4% to €35.9 million.
• Free cash flow edged up 4.7% to €31.4 million; capex-to-sales ratio widened to 9.2% from 6.7%.
• Guidance unchanged at €520 million-€540 million revenue, €168 million-€178 million adjusted EBITDA; now seen toward the upper end, citing defense imaging and night vision demand.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exosens SA published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein.